BLLN at a glance
The past year
Chart+3.3% $105.15, close Nov 13
- From the highest close
- −29.9%
- Vs the 200-day average
- +7.7%
Short interest
History3.0M shares
- Of shares outstanding
- 6.86%
- Since the last report
- +1.3%
- Days to cover
- 6.7 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 9 – Nov 15
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
BLLN price history
Loading recent earnings…
Investment thesis
What must happen next
Clinicians keep ordering BillionToOne’s differentiated prenatal and oncology assays because they solve decision problems not fully met by incumbent genetic tests, so adoption continues to translate into billable tests rather than one-time launch demand.StrengtheningMateriality: High
GAAP annual revenue increased from $71.7 million in FY2023 to $152.6 million in FY2024 and $305.1 million in FY2025. If clinical utility remains differentiated, revenue can compound from repeat physician ordering; if not, growth becomes vulnerable to incumbent labs and payer pushback.
Watch: Natera wins back obstetric practices by matching or exceeding BillionToOne’s prenatal test performance, workflow, or payer access.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $71.7 million in FY2023 to $152.6 million in FY2024 and $305.1 million in FY2025.
Open source ↗BillionToOne’s lab platform retains enough pricing, reimbursement, and cost advantage that higher test volume carries attractive contribution economics instead of becoming commoditized send-out testing.StrengtheningMateriality: High
GAAP annual gross profit rose from $17.3 million in FY2023 to $80.9 million in FY2024 and $208.5 million in FY2025. The business only becomes durable if growth is profitable; payer pressure or commoditization would convert revenue growth into low-quality volume.
Watch: Commercial payers or CMS/MolDX reduce allowed amounts for relevant prenatal or oncology molecular tests.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit rose from $17.3 million in FY2023 to $80.9 million in FY2024 and $208.5 million in FY2025.
Open source ↗The sales, lab, and R&D base becomes more productive as test adoption scales, so incremental gross profit is not fully consumed by commercial expansion and product development.StrengtheningMateriality: Medium
GAAP annual operating income improved from a loss of $69.5 million in FY2023 to a loss of $47.1 million in FY2024 and positive $16.0 million in FY2025. Operating leverage is what turns a promising diagnostics platform into equity value; without it, the company may need constant spending just to maintain growth.
Watch: BillionToOne must materially expand its sales force to maintain order growth because physician adoption is not self-reinforcing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income improved from a loss of $69.5 million in FY2023 to a loss of $47.1 million in.
Open source ↗BillionToOne is moving from externally financed diagnostics growth toward internally financed expansion, giving management room to invest in new assays without repeated emergency dilution.StrengtheningMateriality: Medium
GAAP annual operating cash flow improved from negative $53.7 million in FY2023 to negative $41.4 million in FY2024 and positive $24.6 million in FY2025. Self-funding changes the risk profile: owners benefit more from growth if it can be financed by operations rather than new equity or debt.
Watch: Collections deteriorate because payer denials, appeals, or reimbursement delays rise.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow improved from negative $53.7 million in FY2023 to negative $41.4 million in FY2024 and positive.
Open source ↗The enlarged balance sheet gives BillionToOne flexibility to invest through launch and reimbursement volatility, but it creates per-share value only if capital is directed toward assays with proven clinical adoption rather than unfocused pipeline spending.StrengtheningMateriality: Medium
Cash was $496.0 million at FY2025, up from $191.5 million at FY2024. Cash lowers near-term financing risk, but poor capital allocation could dilute returns even if the science is promising.
Watch: Management pursues acquisitions or pipeline programs outside areas where BillionToOne has demonstrated clinical or commercial advantage.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $496.0 million at FY2025, up from $191.5 million at FY2024.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Clinicians keep ordering BillionToOne’s differentiated prenatal and oncology assays because they solve decision problems not fully met by incumbent genetic tests, so adoption continues to translate into billable tests rather than one-time launch demand. If clinical utility remains differentiated, revenue can compound from repeat physician ordering; if not, growth becomes vulnerable to incumbent labs and payer pushback.
BillionToOne’s lab platform retains enough pricing, reimbursement, and cost advantage that higher test volume carries attractive contribution economics instead of becoming commoditized send-out testing. The business only becomes durable if growth is profitable; payer pressure or commoditization would convert revenue growth into low-quality volume.
The sales, lab, and R&D base becomes more productive as test adoption scales, so incremental gross profit is not fully consumed by commercial expansion and product development. Operating leverage is what turns a promising diagnostics platform into equity value; without it, the company may need constant spending just to maintain growth.
BillionToOne is moving from externally financed diagnostics growth toward internally financed expansion, giving management room to invest in new assays without repeated emergency dilution. Self-funding changes the risk profile: owners benefit more from growth if it can be financed by operations rather than new equity or debt.
The enlarged balance sheet gives BillionToOne flexibility to invest through launch and reimbursement volatility, but it creates per-share value only if capital is directed toward assays with proven clinical adoption rather than unfocused pipeline spending. Cash lowers near-term financing risk, but poor capital allocation could dilute returns even if the science is promising.
All standing thesis claims
Original report summary
its prenatal and oncology molecular tests prove clinically differentiated enough to keep winning orders and reimbursement while lab scale turns that volume into durable cash generation.
Bull case and bear case
Bull case and bear case for BillionToOne
Where the evidence on BillionToOne stands: Strengthening on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 5 strengthening.
Bull case: what the evidence supports
Clinicians keep ordering BillionToOne’s differentiated prenatal and oncology assays because they solve decision problems not fully met by incumbent genetic tests, so adoption continues to translate into billable tests rather than one-time launch demand.
BillionToOne’s lab platform retains enough pricing, reimbursement, and cost advantage that higher test volume carries attractive contribution economics instead of becoming commoditized send-out testing.
The sales, lab, and R&D base becomes more productive as test adoption scales, so incremental gross profit is not fully consumed by commercial expansion and product development.
BillionToOne is moving from externally financed diagnostics growth toward internally financed expansion, giving management room to invest in new assays without repeated emergency dilution.
The enlarged balance sheet gives BillionToOne flexibility to invest through launch and reimbursement volatility, but it creates per-share value only if capital is directed toward assays with proven clinical adoption rather than unfocused pipeline spending.
Bear case: what would count against it
Natera wins back obstetric practices by matching or exceeding BillionToOne’s prenatal test performance, workflow, or payer access.
Commercial payers or CMS/MolDX reduce allowed amounts for relevant prenatal or oncology molecular tests.
BillionToOne must materially expand its sales force to maintain order growth because physician adoption is not self-reinforcing.
Company research
Research on BillionToOne
- Reporting · BillionToOne, Inc. (NASDAQ: BLLN) Stock Is Up 12%: The Investment Case
The molecular diagnostics company has real growth and cash generation, but today's valuation assumes reimbursement and margins stay unusually strong.
Thesis-Break Engine
What has broken in BillionToOne’s thesis
Each break OptimistFi flagged on BillionToOne, dated — with what has historically followed the same kind of break across the market, not a forecast for BillionToOne.
- Insider-selling clustercondition set before this filing
Across all companies, this kind of break has happened 9,137 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 30% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
BillionToOne filed an SEC 8-K on 2026-08-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
BillionToOne filed an SEC 8-K on 2026-06-29: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
BillionToOne filed an SEC 8-K on 2026-06-16: Entered a material definitive agreement. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Natera wins back obstetric practices by matching or exceeding BillionToOne’s prenatal test performance, workflow, or payer access.
- Commercial payers or CMS/MolDX reduce allowed amounts for relevant prenatal or oncology molecular tests.
- BillionToOne must materially expand its sales force to maintain order growth because physician adoption is not self-reinforcing.
- Collections deteriorate because payer denials, appeals, or reimbursement delays rise.
- Management pursues acquisitions or pipeline programs outside areas where BillionToOne has demonstrated clinical or commercial advantage.
BLLN news
Loading headlines…
Financial statements
BLLN income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
BLLN: quick answers
- When does BillionToOne (BLLN) report earnings next?
- BillionToOne's next results are projected for January 20, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 4, 2026. Earnings calendar
- What is BLLN's short interest?
- As of October 30, 2026, 3.0M BLLN shares were sold short, 6.86% of its shares outstanding, up 1.3% from the count before. At the stock's average daily volume that is 6.7 days to cover. FINRA publishes the count twice a month. BLLN short interest history

